Back to School: How biopharma can reboot drug development. Access exclusive analysis here
An FDA advisory committee voted 6-2 on Tuesday to recommend approval of vernakalant IV from Astellas (Tokyo:4503)
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury